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DOI 10.1186/s12885-015-1360-4RESEARCH ARTICLE Open AccessSignificance of KRAS/PAK1/Crk pathway in
non-small cell lung cancer oncogenesis
Fariborz Mortazavi1,2,3*, Jie Lu4, Ryan Phan5, Michael Lewis5, Kenny Trinidad1, Amir Aljilani1,
Gholamhossein Pezeshkpour5 and Fuyuhiko Tamanoi3,4Abstract
Background: Key effector(s) of mutated KRAS in lung cancer progression and metastasis are unknown. Here we
investigated the role of PAK1/Crk axis in transduction of the oncogenic KRAS signal in non-small cell lung cancer (NSCLC).
Methods: We used NSCLC clinical specimens to examine the correlation among KRAS mutations (codon 12, 13 and 61);
PAK1/Crk axis activation [p-PAK1(Thr423), p-Crk(Ser41)]; and adhesion molecules expression by immunohistochemistry.
For assessing the role of proto-oncogene c-Crk as a KRAS effector, we inhibited KRAS in NSCLC cells by a combination of
farnesyltransferase inhibitor (FTI) and geranylgeranyltransferase inhibitor (GGTI) and measured p-Crk-II(Ser41) by western
blotting. Finally, we disrupted the signaling network downstream of KRAS by blocking KRAS/PAK1/Crk axis with
PAK1 inhibitors (i.e., IPA-3, FRAX597 or FRAX1036) along with partial inhibition of all other KRAS effectors by
prenylation inhibitors (FTI + GGTI) and examined the motility, morphology and proliferation of the NSCLC cells.
Results: Immunohistochemical analysis demonstrated an inverse correlation between PAK1/Crk phosphorylation
and E-cadherin/p120-catenin expression. Furthermore, KRAS mutant tumors expressed higher p-PAK1(Thr423)
compared to KRAS wild type. KRAS prenylation inhibition by (FTI + GGTI) completely dephosphorylated proto-oncogene
c-Crk on Serine 41 while Crk phosphorylation did not change by individual prenylation inhibitors or diluent. Combination
of PAK1 inhibition and partial inhibition of all other KRAS effectors by (FTI + GGTI) dramatically altered morphology,
motility and proliferation of H157 and A549 cells.
Conclusions: Our data provide evidence that proto-oncogene c-Crk is operative downstream of KRAS in NSCLC.
Previously we demonstrated that Crk receives oncogenic signals from PAK1. These data in conjunction with the
work of others that have specified the role of PAK1 in transduction of KRAS signal bring forward the importance
of KRAS/PAK1/Crk axis as a prominent pathway in the oncogenesis of KRAS mutant lung cancer.
Keywords: KRAS, PAK1 kinase, c-Crk, E-cadherin, Cell adhesion, Lung cancer, Signal transductionBackground
KRAS mutant lung cancer comprises 25-30% of lung
adenocarcinomas and unfortunately no effective treat-
ment is currently available for this sub-type of non-small
cell lung cancer (NSCLC). One strategy to interrupt the
oncogenic KRAS signal is to block the key downstream
effector(s) of this oncogene. Recently, PAK1 kinase was
shown to play a role in transduction of the KRAS signal
[1-4]. For example, exposure of cells that harbor KRAS
or NRAS mutations to PAK1 inhibitor (IPA-3) resulted* Correspondence: fredmortazavi@ucla.edu
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creativecommons.org/publicdomain/zero/1.0/in cell death while this inhibitor had no effect on BRAF
mutant cells [3]. Furthermore, knockdown of PAK1 in
KRAS mutant colon cancer cells inhibited the prolifera-
tion of these cells independent of Raf/MEK/ERK or
PI3K/Akt pathways [4]. Our data previously showed that
PAK1 phosphorylates adaptor protein Crk and thereby
promotes cell motility and cell invasiveness [5]. Consid-
ering Crk can function as an onco-protein [6-8], we hy-
pothesized that KRAS/PAK1/Crk axis plays a prominent
role in transduction of oncogenic KRAS signal. Here, we
demonstrate that inhibition of KRAS/PAK1/Crk pathway
in conjunction with partial widespread interruption of
KRAS signal dramatically alters the morphology, motility
and proliferation of KRAS mutant NSCLC cells.s article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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Cell cultures
H157 and Rh2 cells were routinely cultured in RPMI sup-
plemented with antibiotics and 10% heat-inactivated FBS
(Omega Scientific, Tarzana, CA) along with Penicillin-
Streptomycin (Life Technologies, Grand Island, NY Cat.
number 15140-122) without any additional L-glutamine.
Western blots
NSCLC cell lines were seeded in 10 cm Petri dishes at 5
x 105 cells per dish, which resulted in 30-40% confluency
24 hours after plating. Cells were harvested at 24 hours
by adding trypsin, pelleted and lysed in 100 μl of lysis
buffer (NaCl 15 mM; EDTA 0.5 mM; Tris 10 mM) using
a Branson Sonifier. Cell debris was collected by centrifuga-
tion at 4°C, and protein concentration was measured by the
BCA method. Protein was resolved by SDS-PAGE and was
transferred to a nitrocellulose membrane. The membrane
was blocked with TBS with 5% nonfat powdered milk.
Membranes were immunoblotted with the following
primary antibodies: PAK1 (Sigma-Aldrich Cat. number
SAB4300427; 1:1000), p-Thr 423 PAK1 (Cell signaling
Cat. Number 2601; 1:1000); E-cadherin (BD biosciences
Cat. number 610181; 1:10,000); p120 catenin (BD biosci-
ences Cat. number 610133; 1:4000); Crk-II (Santa Cruz
Biotechnology Cat. number sc-289; 1:200); p-Ser41 Crk-II
(Santa Cruz Biotechnology Cat. number sc-130186; 1:100).
Horse radish peroxidase conjugated secondary antibodies
were used for detection of bands by chemiluminescence
(ECL western blotting detection reagents, Amersham Bio-
sciences, Piscataway, NJ, USA).
Immunohistochemical stating and determination of
intensity of staining
Paraffin embedded NSCLC clinical specimens from sur-
gically resected specimens at the West Los Angeles
Veterans Administration were selected. Specimens were
formalin fixed, processed and sectioned at 4 μm. The
glass slides were deparaffinized and stained by DAKO
AutostainerLink48 by the following primary antibodies:
PAK1 (Sigma-Aldrich Cat. number SAB4300427); p-Thr
423 PAK1 (Cell signaling Cat. Number 2601); E-Cadherin
(BD biosciences Cat. number 610181); p120 Catenin (BD
biosciences Cat. number 610133); Crk-II (Santa Cruz Bio-
technology Cat. number sc-289); p-Ser41 Crk-II (Santa
Cruz Biotechnology Cat. number sc-130186). Following
tissue staining, the slides were reviewed by two patholo-
gists and the intensity of staining in each slide was ranked
according to a scale from (0 to 3+; No staining was desig-
nated as 0 and strongest staining for each antibody as 3+).
KRAS mutation analysis
The status of KRAS mutation on codon 12, 13 and 61
was examined by sequencing the KRAS exons 2 and 3.Initially, an H&E staining from each tumor specimen
was obtained and reviewed to accurately select tumor
area. Three to five adjacent unstained slides of 5-7 μm
was obtained from the corresponding paraffin-embedded
(FFPE) block and the tumor containing areas was harvested
for extraction of genomic DNA. DNA was extracted and
purified by using Qiagen kit (Life Technologies) according
to the manufacturer’s instructions and DNA quality and
quantity was measured and recorded. Subsequently, we
proceeded to KRAS mutation analysis. We have recently
developed a real-time PCR-based approach to rapidly
screen for mutation of various genes including KRAS by
using in-house developed Taqman probes that specifically
recognize wild type and mutant alleles of each gene. This
methodology has proven to be highly specific and sensitive
and applicable to various sample types including formalin-
fixed paraffin embedded (FFPE) tissue. In this study, KRAS
mutation analysis was performed for specific 12 known
codon 12 and codon 13 mutations. For codon 61 muta-
tions, we sequenced KRAS exon 3.
Wound healing assays and microscopy
A549 and H157 cells were plated in a 6 well plate dish
at 1 x 105 cells per well and were grown to confluent
stage. By using a sterile P1000 pipette tip, a straight
scratch was made along the largest diameter of each well
and a baseline photomicrograph was taken from this
scratch with two different magnifications. A follow up
photomicrograph was taken at 24 hours. Photomicro-
graphs of the cells were obtained by a Nikon Eclipse
TS100 inverted microscope equipped with a Cannon
A510 digital camera. The digital camera was connected
with a Max View Plus adaptor (ScopeTronix) to the
inverted microscope. An equal area of the photomicro-
graphs from each condition was imported into the
Adobe Photoshop software. The wound area was se-
lected by using the Magic Wand Tool of the Adobe
Photoshop and the number of pixels in each selected
area was determined by the Histogram Tool. Experi-
ments were repeated three times and the average wound
surface area was compared among the groups.
Determining cell proliferation
Cells were seeded in 24 well plates and exposed to inhib-
itors [IPA-3 (Tocris Biosciences, Cat. number 3622);
FRAX597 and FRAX1036 (Genentech)] at desired con-
centration. Cells from each well were harvested in tripli-
cates daily and counted by hemocytometer. The mean of
cell counts were plotted over the course of five days.
Ethics
Human subject specimens were deidentified prior to use
in this project. The utilized method was reviewed and
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Results
Phosphorylation of PAK1/Crk is inversely correlated with
E-cadherin/p120-catenin expression in clinical NSCLC
specimens
Our previous work showed that PAK1 phosphorylates
adaptor protein Crk on serine 41 which in turn in-
creases motility and invasiveness of lung cancer cells73
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Figure 1 PAK1 activation and Crk phosphorylation are correlated with loss o
demonstrating immunohistochemical staining of NSCLC clinical specimens. S
expressing no detectable level of p-PAK1(Thr423) and p-Crk-II(Ser41). On the o
p-Crk-II(Ser41) show very low levels of E-cadherin/p120-catenin.[5]. Furthermore, we have shown that adaptor protein
Crk transcriptionally represses (CTNND1) p120-
catenin promoter [9] while loss of p120-catenin has
been shown to result in E-cadherin degradation and
destabilization of adherens junctions [10-12]. Here we
sought to investigate whether PAK1, Crk, p120-
catenin and E-cadherin establish a correlation with
each other in clinical lung cancer specimens. For this
purpose, we examined the expression of PAK1, p-
PAK1(Thr423), Crk-II, p-Crk-II(Ser41), p120-cateninp-PAK1 p-Crk-II in
f E-cadherin and p120-catenin in NSCLC specimens. Photomicrographs
amples 12, 54, 16 and 75 harbor high E-cadherin/p120-catenin while
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Figure 2 PAK1 activation and Crk phosphorylation are positively
correlated while establish a negative correlation with E-cadherin in
NSCLC. Dot plots demonstrating the correlation between A-E-cadherin
and p-PAK1(Thr423); B-E-cadherin and p-Crk-II(Ser41); C-p-PAK1(Thr423)
and p-Crk-II(Ser41) expression by immunohistochemistry in 17 NSCLC
clinical specimens. The average intensity of protein expression across
the slide is quantified in a scale from 0-3+. The correlation between the
expressions of each two marker was examined by utilizing Spearman
Rank Correlation statistical test.
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ded NSCLC specimens.
We observed a concordance between expression of p-
PAK1(Thr423) and p-Crk-II(Ser41) (Figure 1). Interest-
ingly, tumors expressing phosphorylated PAK1/Crk had
very low level of p120-catenin and E-cadherin (Figure 1).
Of note, we did not observe an association between total
PAK1 and Crk-II expression with that of p120-catenin/
E-cadherin (data not shown). In order to examine the
statistical correlation between the intensity of PAK1/Crk
phosphorylation with E-cadherin expression, we quanti-
fied the phosphorylation and expression of these pro-
teins in a scale of 1-3 as described in the Methods
section. Subsequently, the correlation between the inten-
sity of p-PAK1(Thr423), p-Crk-II(Ser41) and E-cadherin
was examined in a Spearman Rank Correlation analysis
(Figure 2). E-cadherin expression in the examined sam-
ples showed a statistically significant negative correlation
with the expression of p-PAK1(Thr423) and p-Crk-
II(Ser41) (p < 0.0072 and p < 0.047 respectively) while p-
PAK1(Thr423) and p-Crk-II(Ser41) established a positive
correlation with each other (p < 0.0097). These findings
highly suggest that PAK1 activation by upstream stimuli
results in Crk mediated suppression of p120-catenin and
E-cadherin in lung cancer.
Furthermore, we examined PAK1 activation and its
correlation with E-cadherin/p120-catenin expression in
a panel of NSCLC cell lines (Figure 3). For this purpose,
we examined the expression of E-cadherin, p120-
catenin, total PAK1 and p-PAK1(Thr423) in a panel of
NSCLC cells. As expected, we observed an inverse cor-
relation between E-cadherin/p120-catenin expression
and the ratio of phospho-PAK1/total PAK1 in the exam-
ined panel of cell lines.
PAK1 activation is correlated with surgical stage at
presentation in NSCLC
Considering we identified that PAK1 activation is closely
correlated with E-cadherin and p120-catenin expression
in our clinical samples, we were facing the question
whether PAK1 activation establishes any association with
tumor stage at presentation. In order to answer this
question, we reviewed the medical records for each case
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Figure 3 PAK1 activation is inversely correlated with E-cadherin and p120-catenin expression in NSCLC cells. A-Western blots demonstrating
E-cadherin, p120-catenin, PAK1 and p-PAK1(Thr423) expression in a panel of NSCLC cells as well as immortalized normal human respiratory
epithelial cells (BEAS-2B). B-Bar chart demonstrating signal intensity of p-PAK1/PAK1, p120-catenin and E-cadherin normalized to the value of
BEAS-2B cells.
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staging (i.e., tumor size and mediastinal nodal involve-
ment) and correlated the results with E-cadherin, p-
PAK1(Thr423) and p-Crk-II(Ser41) expression in our
samples. All examined tumors were surgically removed
so none of the cases had distant metastasis therefore our
cases ranged from Stage I to III. Of note, majority of
resected lung tumors including cases in our repository
are from stage I disease with a limited number of stage
II-III cases. As expected the intensity of E-cadherin ex-
pression established a close correlation with surgical
stage of tumors (Figure 4A). Furthermore, we observed
that the mean of p-PAK1(Thr423) expression was signifi-
cantly higher in stage II/III vs. stage I tumors (Figure 4B).
However, the difference between mean of p-Crk-II(Ser41)
expression in stage I vs stage II/III tumors did not reach
the statistical threshold (Figure 4C). We should mention
that the tumor stage (i.e., tumor size, nodal involvementand distant metastasis) is a function of (i) tumor biology,
and (ii) the time interval that tumor has been growing. In
other words, aggressive tumors generally present at higher
stages (as we see in case of most tumors with activated
PAK1) however we also see one case with no PAK1 activa-
tion and high stage. The high stage of this case can be ex-
plained by the long period of time this tumor has been
growing prior to being detected and surgically removed.
PAK1 is phosphorylated in KRASmutant NSCLC specimens
Mutated KRAS transduces its oncogenic signal through
several downstream effectors. Recently, PAK1 has been
identified as one of the prominent players that transduce
the oncogenic KRAS signal [1-4]. Here we examined
whether PAK1 is activated in KRAS mutant NSCLC
specimens. Towards this end, we examined the presence
of KRAS mutations in codon 12, 13 and 61 by examining
KRAS exons 2 and 3 (as explained in the Methods) and
AB
C
Stage-I            Stage II/III
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
E
-c
ad
h
er
in
E-cadherin by Stage (p<0.035)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
p
-P
A
K
1(
T
h
r4
23
)
p-PAK1 (Thr423) in stage I vs. II/III 
(p<0.024)
Stage-I          Stage II/III
Stage-I       Stage II       Stage III  
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
p
-C
rk
(S
er
41
)
p-Crk (Ser41)in stage I vs. II/III 
(p<0.096)
(n=12)             (n=5)
(n=12)             (n=5)
Figure 4 PAK1 activation is correlated with tumor stage at presentation.
A-Dot plot demonstrating the expression of E-cadherin in the examined
tumors in relation to the surgical stage of each tumor. The correlation
between variables were examined by Spearman Rank Correlation analysis.
B- Dot plot demonstrating the expression of p-PAK1(Thr423) in stage I
and stage II/III tumors. The mean between groups was compared by
student T-test. C- Dot plot demonstrating the expression of p-Crk-II(Ser41)
in stage I and stage II/III tumors. The mean between groups was
compared by student T-test.
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and wild type groups (Figure 5). We observed that KRAS
mutant group demonstrated a statistically significant
higher mean of p-PAK1(Thr423) expression as compared
to samples harboring wild type KRAS (P < 0.0265) “see
Additional file 1”. Furthermore, we did not observe any
KRAS mutant sample that did not express p-
PAK1(Thr423). We should mention that we noticed one
case that carried wild type KRAS along with elevated p-
PAK1(Thr423). This finding suggests that upstream onco-
genes other than mutated KRAS also transduce their
signal through PAK1 (e.g., PI3K) [13]. KRAS mutant sam-
ples also demonstrated lower mean of E-cadherin expres-
sion compared to wild type group however this difference
was not statistically significant. These data further suggest
that PAK1 is activated by mutated KRAS in lung cancer.KRAS prenylation inhibition dephosphorylates Crk-II on
Serine 41
We previously showed that PAK1 phosphorylates Crk-II
on serine 41 [5] as PAK1 silencing dephosphorylated
Crk-II on this residue and the amino acid sequence of
Crk-II at the vicinity of Serine 41 was identical to the
PAK1 phosphorylation sequence site on Raf and also this
sequence showed a high degree of homology to the
PAK1 phosphorylation consensus sequence in other
PAK1 effectors (i.e., MEK, Snail and LIMK-1) [5,14].
Considering PAK1 is shown to be functioning down-
stream of KRAS, we sought to examine whether KRAS
signal is transduced through Crk as well. In order to an-
swer this question, we inhibited KRAS by a combination
of farnesyltransferase inhibition (FTI) and geranylgera-
nyltransferase inhibition (GGTI) in NSCLC cells and ex-
amined Crk phosphorylation. Recently, we developed
novel small molecule geranylgeranyltransferase type I in-
hibitors (GGTIs) [15-18] through a high-throughput
screen. One of the identified GGTIs (i.e., P61A6) has
inhibited both proliferation and cell cycle progression in
a variety of human cancer cell lines including NSCLC
cells [19]. Interestingly, exposure of Rh2 cells to FTI
(BMS-225975) and GGTI (P61A6) combination for 24
hours completely dephosphorylated Crk-II on Serine 41
Figure 5 KRAS mutant NSCLC specimens express higher activated PAK1 compared to KRAS wild type samples. A-Dot plot demonstrating
immunohistochemical expression of p-PAK1(Thr423) in KRAS mutant and KRAS wild type NSCLC clinical specimens. p-PAK1(Thr423) is detectable
in all KRAS mutant specimens while most KRAS wild type samples express lower p-PAK1(Thr423). B- Dot plot demonstrating immunohistochemical
expression of E-cadherin in KRAS mutant vs. KRAS wild type NSCLC clinical specimens.
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the other hand, exposure of each inhibitor individually
had little or no effect on Crk-II phosphorylation. This
finding demonstrates that adaptor protein/proto-oncogene
Crk is functioning downstream of KRAS. Considering (i)
PAK1 is shown to be operative downstream of KRAS [1-4]
and (ii) PAK1 phosphorylates Crk on serine 41 [5], it is
most likely that the link from KRAS to Crk is transduced
through PAK1.Combination of PAK1 inhibition and KRAS prenylation
inhibition cause a dramatic morphological change in
NSCLC cells
KRAS transduces its signal through several downstream
effectors and it is likely that more than one pathway
needs to be inhibited to achieve an effective KRAS signal
blockade. Here, we asked whether inhibition of KRAS/
PAK1/Crk axis provides adequate KRAS signal interrup-
tion when combined with inhibition of other KRAS ef-
fectors. For answering this question, we decided toCrk-II
p-Crk
Ctr.      F+G       F        G
Figure 6 KRAS inhibition dephosphorylates Crk-II on serine 41. Western
blots demonstrating loss of Crk-II phosphorylation on serine 41 in Rh2
NSCLC cells following 24 hour exposure of cells to combination of
(F) farnesyltransferase inhibitor (BMS-225975 at 2 μM) and (G)
geranylgeranyltransferase inhibitor (P61A6 at 2 μM).inhibit PAK1/Crk axis and at the same time partially
interrupt all other KRAS effectors because it is not
known if any KRAS effector predominately transduces
the oncogenic signal. In order to block the KRAS signal
through PAK1/Crk axis, we decided to use a PAK1 in-
hibitor (i.e., IPA-3) while for interruption of all other
KRAS effectors we used KRAS prenylation inhibitors.
Inhibitors of KRAS prenylation prevent membrane as-
sociation of KRAS and thereby inhibit KRAS activation.
Examples include farnesyltransferase inhibitors (FTI)
and geranylgeranyltransferase inhibitors (GGTI). In
order to achieve a successful loss of KRAS prenylation, a
combination of FTI and GGTI is required because if FTI
is used alone, geranylgeranyltransferase type I (GGTase-I)
will compensate for the loss of farnesylation by enhancing
geranylgeranylation of KRAS and consequently resumes
membrane association and transforming activity of KRAS.
We should mention that the required dose of FTI and/or
GGTI that completely blocks the KRAS signal can cause
loss of prenylation in other proteins thereby may result in
severe cellular toxicity. Therefore, tolerable dose of (FTI +
GGTI) partially blocks the KRAS signal.
In fact, addition of PAK1 inhibitor (IPA-3) to (FTI +
GGTI) and exposure of H157 cells to these inhibitors re-
sulted in a prominent loss of cellular motility and a clear
change in cellular morphology in a standard wound
healing assay (Figure 7). H157 cells that have a mesen-
chymal morphology, obtained an epithelial phenotype
with a smooth border when exposed to IPA-3 and (FTI +
GGTI) combination for 48 hours. Of note, exposure of
H157 cells to (FTI + GGTI) or IPA-3 alone did not dem-
onstrate a noticeable effect in the wound healing assay. A
similar but less pronounced effect was observed in A549
cells at 24 hours.
In order to determine whether the observed effects in
wound healing assays were related to changes in cell
500µm
Figure 7 Addition of PAK1 inhibitor to KRAS prenylation inhibitors dramatically alters cell morphology and motility. Photomicrographs of standard
wound healing assays in H157 and A549 cells (KRAS mutant). Cells were exposed to (i) farnesyltransferase inhibitor (BMS-225975 at 2 μM) and
geranylgeranyltransferase inhibitor (P61A6 at 2 μM) [F + G]; (ii) PAK1 inhibitor (IPA-3 at 5 μM); (iii) combination of the three inhibitors or (iv) the
inhibitor vehicles for 24-48 hours.
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as explained under the Methods section following ex-
posure of A549 and H157 cells to IPA-3, (FTI + GGTI),
or combination “see Additional file 2”. In case of H157
cells, changes in cell proliferation started after the first
day of exposure to inhibitors while A549 cells showed
changes in cell proliferation mainly after the second
day of exposure (i.e., after completion of wound heal-
ing assay). These findings demonstrate that combin-
ation of PAK1 inhibitor and prenylation inhibitors also
affect cell proliferation and therefore we conclude that
the observed effect of inhibitors combination on the
course of wound healing assays (Figure 7) seem to a be
in part due to changes in cell motility as well as cell
proliferation.These data demonstrate that blockade of KRAS signal
through PAK1/Crk axis in conjunction with a wide-
spread partial KRAS signal interruption provide ad-
equate disruption of signaling network (downstream of
KRAS) and result in a substantial biological effect. These
findings further emphasize on the role of KRAS/PAK1/
Crk axis as a prominent downstream effector of KRAS
in NSCLC. Furthermore, these data provide evidence
that inhibition of more than one pathway is required to
achieve a noticeable KRAS inhibition.
Combination of PAK1 inhibition and KRAS prenylation
inhibition dephosphorylates ERK
KRAS transduces its signals through several downstream
effectors including PAK1, Raf/MEK/ERK, RalGDS, PDK1,
ERK2
p-ERK 1/2
Figure 8 Addition of PAK1 inhibitor to KRAS prenylation
inhibitors dephosphorylated ERK. Western blots demonstrate
ERK dephosphorylation following 24 hour exposure of Rh2 cells
to (F) farnesyltransferase inhibitor (BMS-225975 at 2 μM), (G)
geranylgeranyltransferase inhibitor (P61A6 at 2 μM), combination
of the two (F + G), or (F + G) along with PAK1 inhibitor (FRAX597
at 40 μM).
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Here we sought to investigate whether KRAS prenylation
inhibition along with PAK1 inhibition might affect KRAS
effectors other than Crk. For this purpose we exposed Rh2
cells to FTI (BMS-225975); GGTI (P61A6); combination
of the two (FTI + GGTI); and also (FTI + GGTI) along
with PAK1 inhibitor (FRAX597, Genentech). Interestingly,
neither FTI/GGTI nor their combination could alter ERK
phosphorylation however addition of PAK1 inhibitor (i.e.,
FRAX597) to (FTI + GGTI) significantly dephosphorylated
ERK (Figure 8).Combination of PAK1 inhibition and KRAS prenylation
inhibition alters proliferation of NSCLC cells
Considering downstream effectors of both PAK1 and
KRAS include modulators of cell proliferation, we inves-
tigated whether inhibition of PAK1 along with KRAS
prenylation inhibition may alter proliferation of NSCLC
cells. Towards this end, we exposed A549 and H157
cells to (i) prenylation inhibitors [i.e., combination of
FTI (BMS-225975) and GGTI (P61A6) at 500 nM each],
(ii) PAK1 inhibitor (FRAX1036 at 10 μM, Genentech),
(iii) prenylation inhibitors and PAK1 inhibitor, and (iv)
inhibitors’ vehicle (Figure 9). H157 cells continued to
grow in the presence of either prenylation inhibitors or
PAK1 inhibitor at the above mentioned concentrations
however combination of prenylation inhibitors and
PAK1 inhibitor synergistically reduced the proliferation
of these cells. On the other hand, proliferation of A549
cells were affected by PAK1 or prenylation inhibitors to
some extent nevertheless combination of PAK1 and pre-
nylation inhibitors showed a much stronger effect in
halting the proliferation of A549 cells.Discussion
KRAS mutations comprise a large fraction of driving
mutations in a variety of tumors. While this abnormality
has been the focus of intense investigations, there has
been little success in counteracting the oncogenic effects
of KRAS. Direct KRAS targeting has proven to be diffi-
cult because several different mutations in codon 12, 13
and 61 of KRAS can produce a dysfunctional protein
that has lost its ability to relieve from activation. Other
strategies for interruption of oncogenic KRAS signals
have been employed such as inhibiting post-translational
modification and membrane association of Ras proteins.
C-terminal farnesylation of Ras is critical for Ras
localization to the plasma membrane and for Ras bind-
ing to effector molecules in the various downstream sig-
naling pathways [20-24]. Multiple approaches have been
utilized to interfere with Ras binding to the plasma
membrane with limited success including (i) farnesyl-
transferase inhibition (FTI); (ii) inhibition of Ras-converting
enzyme-1 (RCE1) and isoprenylcysteine carboxylmethyl-
transferase (ICMT); (iii) employment of farnesyl moiety-
containing molecules, and (iv) geranylgeranyltransferase
type I (GGTase-l) inhibition [25]. Several FTIs have been
developed and tested in clinical settings including
Tipifarnib (R115777) and Lonafarnib (SCH66336) but
unfortunately clinical trials in pancreatic cancer did
not show any clinical benefit of using FTIs alone. The
failure of FTIs could be because of the addition of a
geranylgeranyl group by GGTase-I which can effect-
ively substitute for the farnesyl group and thereby
support Ras membrane association and resume trans-
forming activity. This notion supports strategies to
combine FTI with GGTI for effective loss of KRAS
prenylation. Despite the above, previous generation of
GGTIs demonstrated significant toxicity when com-
bined with FTI at the required concentration to
achieve loss of KRAS prenylation [26]. We should
mention that, prenylation inhibitors affect prenylation
of many proteins other than KRAS therefore only a
limited dose of these inhibitors can be tolerated and
the tolerable dose of (FTI + GGTI) combination most
likely provides a partial blockade of the oncogenic
KRAS signal.
Blocking the downstream KRAS effectors has also
come forward as a promising strategy to block the
oncogenic KRAS signal. Several downstream signaling
pathways transduce KRAS signal including PAK1, Raf/
MEK/ERK, RalGDS, PDK1, Tiam1 and phospholipase
C-epsilon (PLCξ) among others however it is not clear
if any of these pathways exclusively transduce the
oncogenic KRAS signal. Most likely, each downstream
pathway participates in one or more aspects of
KRAS mediated oncogenesis (e.g., proliferation, inva-
sion/metastasis, apoptosis resistance, etc.). Therefore,
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Figure 9 Addition of PAK1 inhibitor to KRAS prenylation inhibitors alters the proliferation of NSCLC cells. Line charts demonstrating mean cell
count of H157 and A549 cells upon exposure to prenylation inhibitors [FTI (BMS-225975) and GGTI (P61A6) at 500 nM each], PAK1 inhibitor
(FRAX1036 at 10 μM) or combination in comparison to cells exposed to inhibitors’ diluent (DMSO).
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most likely requires signal inhibition in more than one
downstream pathway.
Considering inhibition of multiple downstream path-
ways might not be easily achievable, we reasoned that
blockade of a prominent downstream pathway can be
enhanced by addition of widespread partial blockade of
KRAS signals. Therefore, we chose to utilize a PAK1 in-
hibitor [an inhibitor that blocks one of the prominent
KRAS downstream pathways] and then add (FTI +
GGTI) [which provide a partial signal blockade in all
downstream KRAS effectors] for enhancing signal inter-
ruption of KRAS. As shown in Figures 7 and 9, this com-
bination remarkably altered morphology, motility andproliferation of NSCLC cells. It appears that combination
of prenylation inhibitors and PAK1 inhibitor adequately
disrupt the signaling network downstream of KRAS
(Figure 10) and provide a prominent anti-tumor effect.
It is noteworthy that the observed synergy between pre-
nylation inhibitors and a PAK1 inhibitor will provide
the opportunity to use a low concentration of each in-
hibitor for blocking KRAS signals and thereby will en-
able us to avoid the risk of cellular toxicity.
Conclusion
Recent evidence has emphasized on the role of PAK1
in transduction of KRAS oncogenic signal [1-4]. Our
data here further support this role as we observed
Figure 10 Cooperative disruption of signaling network downstream of mutated KRAS. Schematic view of KRAS/PAK1/Crk signaling pathway is
demonstrated. Partial inhibition of KRAS signaling output by tolerable dose of prenylation inhibitors (i.e., FTI + GGTI) in addition to inhibition of a
prominent KRAS effector (i.e., PAK1) result in dramatic anti-tumor effects. FTI: farnesyltransferase inhibitor, GGTI: geranylgeranyltransferase inhibitor,
PAK1I: p21 associated kinase 1 inhibitor.
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KRAS wild type clinical specimens. Furthermore, we
provide data that proto-oncogene Crk is operative
downstream of KRAS and the link from KRAS to Crk
seems to be via PAK1. In summary, presented data
introduce KRAS/PAK1/Crk axis (Figure 10) as one of
the prominent signaling pathways downstream of mu-
tated KRAS in lung cancer. In addition, we provide
evidence that interruption of oncogenic KRAS signal is
achievable by addition of Ras prenylation inhibitors to
the inhibitors of prominent KRAS effectors. Thesefindings also support the notion that inhibition of mul-
tiple KRAS effectors are required to achieve a notice-
able biological effect.Additional files
Additional file 1: KRAS mutant NSCLC specimens express higher
p-PAK1 compared to KRAS wild type specimens. Box plots
demonstrating distribution of p-PAK1 and E-cadherin expression
measured by IHC in NSCLC specimens.
Mortazavi et al. BMC Cancer  (2015) 15:381 Page 12 of 12Additional file 2: Proliferation rate of A549 and H157 cells following
exposure to IPA-3, prenylation inhibitors or combination. Line charts
demonstrating the mean cell count of A549 and H157 cells following
exposure to IPA-3 (5 μM); F: farnesyltransferase inhibitor; G: geranylgeranyl-
transferase inhibitor (500 nM each) or combination.
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